4D Molecular Therapeutics, Inc. (FDMT) Fundamental Analysis: Bull vs. Bear Case

FDMT

4D Molecular Therapeutics, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/10/2026

Business Summary

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

VALUATION

P/E

-3.88

Market Cap ($M USD)

$479.63M

Forward P/E

-4.81

PEG

-0.25

PRICE TO SALES

5.44 PRICE TO BOOK

1.38 EV / EBITDA

-2.39

5-Year Average P/E

Free Cash Flow Yield

-27.12%

DCF Value

$-11.01

Graham Number

N/A

Price to FCF

-3.69

EV to FCF

-3.29

Earnings Yield

-25.76%

FCF Yield

-27.12%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.36

Next Year EPS Growth Estimate

-$1.91

Next Year Revenue Growth Estimate

$29.59B

Return on Equity (ROE)

-36.83%

FREE CASH FLOW

Operating Margin

-203.47%

Debt-to-Equity

0.04 Piotroski F-Score

2 Altman Z-Score

2.33 Return on Invested Capital (ROIC)

-38.24%

Current Ratio

9.34 Quick Ratio

9.34 Net Debt to EBITDA

0.29 Interest Coverage

0.00 Gross Profit margin

-12.45%

FCF PER SHARE

$-1.91

REVENUE PER SHARE

$1.30

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing FDMT, with its snapshot price trading below its DCF value. The Forward P/E and Earnings Yield are deep in the negative, signaling a company struggling with profitability. However, the Altman Z-score of 2.92 suggests it’s not on the brink of financial distress. The negative PEG ratio indicates potential undervaluation if growth materializes, but the current financial health raises red flags about execution risks. Overall, the valuation reflects a high-risk, high-reward scenario.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, FDMT is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, potentially enhancing R&D efficiency. However, execution will be key in translating tech potential into tangible results.

The Bull Case

For the value-driven investor, FDMT's low Debt/Equity ratio of 0.04 and high Current Ratio of 9.34 highlight a robust balance sheet. Despite negative ROIC and FCF Yield, the company's ability to maintain liquidity and a Buy consensus rating suggests institutional confidence. The potential for explosive sales growth next year could unlock significant upside if management capitalizes on its capital efficiency.

The Bear Case

FDMT faces significant structural risks, with a Price/Sales ratio of 6.01 and a Price/Book of 1.53, indicating it might be overvalued relative to its fundamentals. The negative operating margin of -203.47% and gross profit margin of -12.45% reveal severe profitability challenges. Trading close to its 52-week high, the stock appears technically overextended, raising concerns about its sustainability at these levels.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$33.00

Institutional Ownership %

1-Year Beta

2.76 Insider Buying % (6 Mo)

Distance to 52-Week High

34.50%

Distance to 52-Week Low

62.07%

EARNINGS SURPRISE %

-4.12%

50-DAY SMA

$9.49

200-DAY SMA

$9.05

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.